, ,UK UK AureliaAurelia BioscienceBioscience Ltd,Ltd, BioCityBioCity NottinghamNottingham Email:Email: [email protected]@aureliabio.com , UK Aurelia Bioscience Ltd, BioCity Nottingham *Please*Please turnturn overover forfor examples examples ofof availableavailable kinaseskinases , UK UK , UK , Aurelia Bioscience Ltd, BioCity Nottingham BioCity Ltd, Bioscience Aurelia Aurelia Bioscience Ltd, BioCity Nottingham Aurelia Bioscience Ltd, BioCity Nottingham BioCity Ltd, Bioscience Aurelia , UK , Aurelia Bioscience Ltd, BioCity Nottingham BioCity Ltd, Bioscience Aurelia , UK , Aurelia Bioscience Ltd, BioCity Nottingham BioCity Ltd, Bioscience Aurelia Web: www.aureliabio.com Tel : Email: [email protected] +44 (0) 115 8370503 Web: www.aureliabio.com www.aureliabio.com Web: Web: : : Tel Tel [email protected] [email protected] Email: Email: Email: [email protected] Tel : Web: www.aureliabio.com Web: www.aureliabio.com Web: : Tel [email protected] Email: +44 (0) 115 8370503 8370503 8370503 115 115 (0) (0) +44 +44 +44 (0) 115 8370503 +44 (0) 115 8370503 8370503 115 (0) +44 Web: www.aureliabio.com Web: : Tel [email protected] Email: +44 (0) 115 8370503 8370503 115 (0) +44 *Please turn over for examples of available kinases available of examples for over turn *Please *Please turn over for examples of available kinases kinases available available of of examples examples for for over over turn turn *Please *Please *Please turn over for examples of available kinases *Please turn over for examples of available kinases ofof rangerange wide wide aa to to applicableapplicable is is technique technique This This • • *Please turn over for examples of available kinases available of examples for over turn *Please allosteric allosteric atat looklook toto usedused bebe can can approach approach The The • • --off KK andand rate) rate) (association(association -onon K- K thethe ExaminesExamines •• assayassay bindingbinding biochemicalbiochemical pseudopseudo kinases of range wide a to applicable is technique This • releaserelease toto digitonin) digitonin) (with(with disrupteddisrupted bebe cancan CellsCells •• kinases of range wide a to applicable is technique This • kinases of range wide a to applicable is technique This • to a wide range of kinases • This technique is applicable kinases of range wide a to applicable is technique This • inhibitors competitive ATP to addition in inhibitors allosteric at look to used be can approach The • length -length - full full inhibitors competitive ATP to addition in inhibitors allosteric at look to used be can approach The • competitive inhibitors inhibitors competitive ATP to addition in inhibitors allosteric at look to used be can approach The • • The approach can be used to look at allosteric inhibitors in addition to ATP cellscells in in targettarget kinasekinase of of ExpressionExpression • • inhibitors competitive ATP to addition in inhibitors allosteric at look to used be can approach The • kinases of range to a wide applicable is technique This • cells live in compounds of rate) (dissociation off - K and rate) (association on - K the Examines • cells live in compounds of rate) (dissociation off - K and rate) (association on - K the Examines • in live cells cells live in compounds of rate) (dissociation off - K and rate) (association on - K the Examines • • Examines the K-on (association rate) and K-off (dissociation rate) of compounds IntracellularIntracellular bindingbinding compoundcompound of of examinationexamination •• cells live in compounds of rate) (dissociation off - K and rate) (association on - K the Examines • assay binding biochemical pseudo assay binding biochemical pseudo biochemical pseudo pseudo biochemical binding assay assay binding inhibitors competitive to ATP addition in inhibitors allosteric to look at be used can approach The • assay assay assay binding biochemical pseudo from content cellular release to digitonin) (with disrupted be can Cells • a as performed be can assay the and cell the a as performed be can assay the and cell the from content cellular release to digitonin) (with disrupted disrupted be be can can Cells Cells • • • Cells can be disrupted (with digitonin) to release cellular content from the cell and the assay can be performed as a a as performed be can assay the and cell the from content cellular release to digitonin) (with compound compound profile profile to to technique technique biophysical biophysical FirstFirst • • a as performed be can assay the and cell the from content cellular release to digitonin) (with disrupted be can Cells • cells live in of compounds rate) (dissociation K-off and rate) K-on (association the Examines • length - full cells in target kinase of Expression • length - length - full full full-length cells cells in in target target kinase kinase of of Expression Expression • • • Expression of kinase target in cells length - full cells in target kinase of Expression • ATP physiological Intracellular cells live in concentrations at kinase target to binding compound of examination • assay binding biochemical pseudo AdvantagesAdvantages :: ATP physiological Intracellular Intracellular Intracellular physiological ATP ATP physiological cells live in concentrations at kinase target to binding compound of examination • examination • • examination of compound binding to target kinase at concentrations in live cells cells live in concentrations at kinase target to binding compound of ATP physiological Intracellular cells live in concentrations at kinase target to binding compound of examination • assay assay assay assay as a performed be assay can the and the cell from content cellular to release digitonin) (with be disrupted can Cells • assay intracellular for binding compound profile to technique biophysical First • pharmacology functional truly – targets pharmacology pharmacology functional functional truly truly – – targets targets intracellular intracellular for for binding binding compound compound profile profile to to technique technique biophysical biophysical First First • • • First biophysical technique to profile compound binding for intracellular targets – truly functional pharmacology pharmacology functional truly – targets intracellular for binding compound profile to technique biophysical First • length full- in cells target kinase of Expression • Advantages : Advantages Advantages Advantages : : : Advantages : duringduring compoundcompound SAR SAR developmentdevelopment ATP physiological Intracellular cells in live concentrations kinase at to target binding of compound examination • (B) and the residence time (C) of compounds (B) and the residence time (C) of compounds assay CompetitiveCompetitive inhibitioninhibition (A)(A) ofof compound compound binding binding toto DDR1DDR1 kinasekinase in in livingliving cells.cells. SS during compound SAR development SAR compound during pharmacology functional – truly targets for intracellular binding compound profile to technique • First biophysical during compound SAR development SAR compound during during compound SAR development development SAR compound during during compound SAR development SAR compound during (B) and the residence time (C) of compounds compounds of (C) time residence the and (B) binding parameter evaluation evaluation parameter binding kinetic allows kinase target the at binding parameter evaluation evaluation parameter binding kinetic allows kinase target the at compounds of (C) time residence the and (B) (B) and the residence time (C) of compounds compounds of (C) time residence the and (B) (B) and the residence time (C) of compounds at the target kinase allows kinetic binding parameter evaluation evaluation parameter binding kinetic allows kinase target the at binding parameter evaluation evaluation parameter binding kinetic allows kinase target the at compounds of (C) time residence the and (B) AA Advantages both the association rate rate association the both tudying S cells. living in kinase DDR1 to binding compound of (A) inhibition Competitive : Competitive inhibition (A) of compound binding to DDR1 kinase in living cells. S S cells. cells. living living in in kinase kinase DDR1 DDR1 to to binding binding compound compound of of (A) (A) inhibition inhibition Competitive Competitive both the association rate rate rate association association the the both both tudying tudying Competitive inhibition (A) of compound binding to DDR1 kinase in living cells. Studying both the association rate Competitive inhibition (A) of compound binding to DDR1 kinase in living cells. S cells. living in kinase DDR1 to binding compound of (A) inhibition Competitive both the association rate rate association the both tudying A B A A A A C B B B B C C C C during compound SAR development binding parameter evaluation allows kinetic target kinase at the (B) and the residence time (C) of compounds A both the association rate tudying Competitive inhibition (A) of compound binding to DDR1 kinase in living cells. S A A A A A B C . kinasekinase targettarget the the for for . kinase target the for . kinase target the for the ofof affinity affinity intracellularintracellular thethe ofof quantitation quantitation . kinase target the for for the target kinase. kinase target the for tracer compound test the of affinity intracellular the of quantitation tracer compound test the of affinity intracellular the of quantitation A signal, signal, ™™ NanoBRETNanoBRET inin decrease decrease dependent dependent permeable - cell a using format ™ NanoBRET fluorescent